Table 3.
Cardiac biomarkers and risk of re‐hospitalization
| 1st re‐hospitalization | ||
|---|---|---|
| HR (95% CI) | P‐value | |
| Cystatin C (n = 257; 89 events) | ||
| Model 1 | 1.33 (1.08–1.65) | 0.008 |
| Model 2 | 1.27 (1.01–1.59) | 0.040 |
| NT‐proBNP (n = 261; 89 events) | ||
| Model 1 | 1.39 (1.10–1.77) | 0.007 |
| Model 2 | 1.43 (1.10–1.87) | 0.009 |
| Copeptin (n = 258; 88 events) | ||
| Model 1 | 1.20 (0.96–1.49) | 0.115 |
| Model 2 | 1.20 (0.94–1.53) | 0.152 |
| MR‐proADM (n = 249; 81 events) | ||
| Model 1 | 1.28 (1.02–2.61) | 0.031 |
| Model 2 | 1.22 (0.93–1.596) | 0.150 |
| CT‐pro‐ET‐1 (n = 260; 89 events) | ||
| Model 1 | 1.30 (1.04–1.62) | 0.019 |
| Model 2 | 1.22 (0.95–1.57) | 0.115 |
CI, confidence interval; CT‐pro‐ET‐1, C‐terminal pro‐endothelin‐1; HR, hazard ratio; MR‐proADM, mid‐regional pro‐adrenomedullin; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
Cox regressions: Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, body mass index, diabetes status, smoking, atrial fibrillation, systolic blood pressure at admission, total cholesterol, high‐density lipoprotein, and New York Heart Association class at admission.